AzTrials
AzTrials

ArteriopathySOFtPERIPHERALNCT03546881

Safety of Fusion Guidance During Peripheral Revascularisation

A study testing fusion imaging guidance technology and 2D X-ray screen in people with Arteriopathy, run by Nantes University Hospital at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arteriopathy
What is being tested?
fusion imaging guidance technology and 2D X-ray screen
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
77 participants
Where
1 siteFrance
Study dates
18 Jun 2018to 16 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing and able to give informed consent
  • Male or Female
  • Aged 18 or older
  • Have been scheduled for peripheral endovascular revascularisation of an occlusive arterial disease excluding isolated infra popliteal revascularisation
  • Who have had a pre-operative diagnostic CT scan
  • Able (in the investigator's opinion) and willing to comply with the study requirements
  • Covered by the French public health insurance system

Who cannot join

  • Female under the age of 50 years old.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Any patient requiring an associated procedure: renal or mesenteric angioplasty.
  • Adult under guardianship or trusteeship

Trial locations and contacts

1 site in 1 country.

France1 site
  • Nantes University Hospital, Vascular surgery, Institut du Thorax

    Nantes, 44093

Other trials in France

About this study

Official title: A Prospective Single Center Randomized Interventional Controlled Open Trial Comparing Patient and Staff Safety During Peripheral Endovascular Arterial Revascularisation Using Advanced Imaging Guidance Technology to Control Group Without Imaging Guidance.

Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease.

Read the detailed description

The investigators are proposing a prospective, monocentric trial to assess the use of fusion imaging in peripheral endovascular revascularisation. The main aim of this research is to prove that using fusion imaging guidance during peripheral endovascular revascularisation improve the patient and staff safety in the theatre, through a reduction of radiation exposure.

Peripheral artery occlusive disease (PAOD) is a worldwide well known disease, with atherosclerosis as a leading cause. One third of patients with PAOD are symptomatic, typically presenting with claudication, and in a very much less proportion with critical limb ischemia. These last patients are high risk for major limb amputation without revascularisation. Once symptomatic PAOD diagnosed, a CT-scan is required to assess the anatomy and if indicated an endovascular revascularisation of the lower limbs arteries is performed. This minimally invasive procedure allows the improvement of the hemodynamic flow into the lower limb, by positioning one or several stents inside the diseased arteries through a femoral or an humeral access under live X-rays (fluoroscopy) guidance.

X-rays are good at showing bones and radio-opaque endovascular tools, but they do not show soft tissues like the arteries, and they produce flat (2D) images that superimpose all the 3D anatomical features. In order to see the arteries, physicians have to inject iodinated contrast during high quality imaging recording, which can be toxic for the kidneys, and increases the amount of radiation used. Consequently, the drawbacks of this mini-invasive procedure are the X-rays radiation exposure for both patients and medical staff, and the need of iodinated contrast injection that can lead to lifelong kidney problems. Reducing both in order to decrease their respective toxicities must be a priority for the endovascular therapist. Several studies including guidelines recall basic safety standards for protection against X-rays and iodinated contrast exposure.

One way to reduce both radiation and contrast use is to improve clinicians' perception of intraoperative 3D vascular anatomy. Advanced imaging techniques allow overlay of a 3D version of the aorta from a pre-operative CT scan (a 3D vascular mask) onto the live X-ray image creating a '3D roadmap' - a virtual reality that helps guide surgery. It has been proven that using fusion imaging guidance during aortic endovascular repair reduce both contrast and radiation dose, especially if the registration protocol is contrast and almost radiation free. The investigators have recently completed research showing that they are able to use an advanced imaging application to dramatically reduce our radiation dose for complex aneurysms.

Traditionally, this advanced imaging application is currently available only in modern expensive hybrid theatres, and not used in everyday practice during peripheral endovascular revascularisation procedures. However new technologies are about to supply similar imaging to any interventional equipment, which will change the way endovascular procedures are performed worldwide. That's why using fusion imaging guidance routinely as a standard of care may be part of good practice to improve patient and staff safety. However, to our knowledge, the impact of using fusion on radiation dose and contrast use has not been validated for peripheral endovascular procedures.

This trial will examine the clinical benefits of using fusion imaging guidance during peripheral endovascular revascularisation procedures based on the radiation exposure, as compared with procedures without imaging guidance. The design of the study is to compare a prospective single centre cohort of 88 consecutive patients scheduled for an endovascular peripheral procedure and randomised either as using the imaging guidance overlay, or to a control cohort of patients whose procedure will be performed without imaging guidance (standard of care).

This study is a Low risk and constraints study, because it's a standard care procedure with no additional risks.

Conditions
Arteriopathy
Being tested
fusion imaging guidance technology, 2D X-ray screen
Keywords
PAOD, endovascular, fusion, radiation, exposure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • fusion imaging guidance technologyProcedure or surgery

    Imaging fusion guidance overlay used during PAOD endovascular revascularisation

  • 2D X-ray screenProcedure or surgery

    2D X-ray screen during PAOD endovascular revascularisation

Study groups in NCT03546881
Study groupRoleWhat they receive
Arm with fusion imaging guidance technologyExperimentalarm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
Receives: Procedure: fusion imaging guidance technology; Procedure: 2D X-ray screen
Arm without fusion imaging guidance technologyActive comparatorarm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
Receives: Procedure: 2D X-ray screen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DAP (Dose Aera Product in Gy.cm²) by the end of the procedure,

    The DAP is a surrogate measurement for the entire amount of energy delivered to the patient by the beam.

    Measured: day 0, per procedure

Secondary outcomes (6)
  1. AK (Air Kerma, in Gy)

    an indirect measurement automatically reported by the fluoroscopy equipment thus highly reproducible and responsive to change in X-rays emission

    Measured: day 0, per procedure

  2. Number of DSA (Digital Subtraction Angiography) runs

    runs (Digital subtraction angiography) along the procedure. The DSA allows high quality loop acquisition with subtraction of non-vascular structures that requires substantial additional radiation exposure compared with standard fluoroscopy

    Measured: day 0, per procedure

  3. FT (Fluoroscopy Time, min).

    a counting of the time spent using fluoroscopy.

    Measured: day 0, per procedure

  4. Radiation exposure to the operator (Sv).

    The operator's exposure to radiation, recorded by a live dosimeter

    Measured: day 0, per procedure

  5. Iodinated contrast volume (ml).

    repeated injections of contrast media contribute to the development of lifelong nephropathy, predominantly in patients with diabetic nephropathy (19.7%) and pre-existing renal impairment (3%-33%)

    Measured: day 0, per procedure

  6. Total operative time ( min)

    time of the operation, between the first puncture and the end of the procedure

    Measured: day 0, per procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2018
  2. Study start18 Jun 2018
  3. Primary completion16 Oct 2019
  4. Study completion16 Oct 2019

Why it stopped: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
77 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03546881
Sponsor's protocol ID
RC17_0473
Acronym
SOFtPERIPHERAL
Status last verified
May 2023
First submitted
23 May 2018
Last updated
23 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing fusion imaging guidance technology and 2D X-ray screen in people with Arteriopathy, run by Nantes University Hospital at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 23 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DAP (Dose Aera Product in Gy.cm²) by the end of the procedure, (time frame: day 0, per procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2023; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in